PBAC changes end in delay

Posted 7 April 2021 AM

PBAC's process improvements have the potential to delay PBS listings even further - just one problem in a system that needs to be made more robust and future fit, according to Biogen managing director Kylie Bromley.

"Certainly the Department and PBAC have made some good efforts with streamlined pathways but in some cases that has actually created potential further delays for the listing of products," she said.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here